Safety and Efficacy of Upadacitinib in Patients with Active Rheumatoid Arthritis Refractory To Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-BEYOND): a Double-Blind, Randomised Controlled Phase 3 Trial
Lancet 2018;391:2513–24
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Lancet 2018;391:2513–24
Rheumatol Ther. 2018 Dec;5(2):341-353. doi: 10.1007/s40744-018-0113-7
Clin Pharmacol Drug Dev. 2019 Feb;8(2):208-216. doi: 10.1002/cpdd.462
Drug Saf 2018 Apr; 41(4):357–61 DOI: 10.1007/s40264-017-0622-2
Pharmacoeconomics 2018 Jul; 36(7):769–78
Pharmacoeconomics 2018 Sep; 36(9): 1063–72
Arthritis Res Ther 2018; 20(1):60 doi: 10.1186/s13075-018-1539-6
Arthritis Res Ther 2018; 20(1):57 doi: 10.1186/s13075-018-1541-z
Rheumatol Ther 2018 Jun; 5(1):203–14. DOI: 10.1007/s40744-018-0093-7